Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
Go back to Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026| (NASDAQ: KURA) | Delayed: 11.73 +0.01 (0.09%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.72 | 52 Week High | $8.90 | |||
| Open | $11.64 | 52 Week Low | $2.50 | |||
| Day High | $11.84 | P/E | N/A | |||
| Day Low | $11.56 | EPS | $0.00 | |||
| Volume | 2,665,263 | |||||
